J84.01 Alveolar proteinosis

Name of the Condition

• Alveolar proteinosis

Summary

Alveolar proteinosis is a rare lung condition characterized by the accumulation of surfactant-derived lipoproteins within the alveoli, impairing gas exchange. This buildup leads to respiratory symptoms and reduced lung function. The condition may be idiopathic or secondary to other underlying factors.

Causes

Alveolar proteinosis can result from impaired clearance of surfactant by alveolar macrophages or overproduction of surfactant. Secondary forms may be associated with hematologic malignancies, immunodeficiency, or inhalation of inorganic dusts. The exact cause of idiopathic cases remains unclear.

Risk Factors

• Exposure to inorganic dusts (e.g., silica, titanium dioxide).
• Hematologic malignancies (e.g., leukemia, lymphoma).
• Immunodeficiency states (e.g., HIV, post-transplant immunosuppression).
• Autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus).

Symptoms

• Progressive shortness of breath (dyspnea), often at rest.
• Dry cough without sputum production.
• Fatigue and reduced exercise tolerance.
• Low-grade fever or malaise in some cases.

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, high-resolution CT (HRCT) of the chest showing characteristic "crazy-paving" patterns, and bronchoalveolar lavage (BAL) revealing milky fluid with periodic acid-Schiff (PAS)-positive material. Lung biopsy may be performed to confirm the diagnosis in atypical cases.

Treatment Options

• Whole-lung lavage: A therapeutic procedure to remove accumulated material from the lungs.
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy: Used in cases with GM-CSF autoantibodies or genetic mutations.
• Supportive care: Oxygen therapy for hypoxemia and pulmonary rehabilitation to improve function.

Prognosis and Follow-Up

Prognosis varies; some patients experience spontaneous remission, while others require ongoing treatment. Regular follow-up with pulmonary function tests and imaging is essential to monitor disease progression or recurrence. Mortality is associated with severe respiratory failure or underlying comorbidities.

Complications

• Respiratory failure due to impaired gas exchange.
• Secondary infections from impaired lung clearance.
• Progression to pulmonary fibrosis in rare cases.

Lifestyle & Prevention

• Avoid exposure to inorganic dusts and occupational hazards.
• Maintain good respiratory hygiene to reduce infection risk.
• Engage in regular, moderate exercise to preserve lung function (as tolerated).

When to Seek Professional Help

Seek immediate medical attention if experiencing sudden worsening of shortness of breath, chest pain, or high fever, as these may indicate acute respiratory decompensation or infection.

Tips for Medical Coders

• Code J84.01 is specific to alveolar proteinosis and should be used when documentation confirms the diagnosis.
• Ensure clinical documentation supports the diagnosis, including findings from imaging, BAL, or biopsy.
• Differentiate from secondary causes (e.g., malignancy, immunodeficiency) to avoid miscoding, as these may require additional codes.